Overview

Product Overview

Brochure

Brochure

Tech Specifications

Tech Specifications

Clinical data

Clinical Data

Sirolimus Eluting Tapered Coronary stent system

BioMime Morph - Drug Eluting Stent

  • 0.3%

    STENT THROMBOSIS

  • 2%

    MACE AT 12 MONTHS IN BIOMIME MORPH MULTICENTER STUDY

  • 99.4%

    FREEDOM FROM TARGET LESION FAILURE (TLF) AT 6 MONTHS IN MORPH INDIA STUDY

BIOMIME MORPH

  • Proven benefits of BioMime, now available as a tapered stent system. Treat long diffused lesions with a single stent – one and done.
  • Long diffused lesions are typically treated through multiple overlapping stents, which are associated with higher rate of restenosis/ revascularization.
  • Biomime MorphTM tapers as per vessel anatomy, it helps avoid multiple stent placement thus reducing the probability of fracture and restenosis.
  • Biomime MorphTM is a Sirolimus Eluting Tapered Coronary Stent System with an ultra-thin 65 µm strut thickness. This next generation SES has a Novel Hybrid Design with closed cells (on both ends of the stent) & open cells (in the middle) - this allows for Morphology Mediated Expansion for adequate conformability and lesser edge dissections.
  • BioPoly Biodegradable Polymer: 2µm low thickness, stable and elastic polymer
  • Stent design with non-linear S links & Y connectors allows for high flexibility and adequate side branch access.
  • Strut width variability ensures optimal radial strength. 
BioMime Morph: Drug Eluting Stent

Benefits

01

Avoids overlapping and associated restenosis and revascularization.

02

Tapers as per vessel anatomy.

03

Reduces procedural time as single stent is deployed.

04

Economical – one stent versus use of multiple overlapping stents.

05

Avoids excessive radiation and contrast.

Product Specifications

Stent material  Cobalt Chromium L605
Stent architecture Hybrid Cell Design with Non-Linear links
Stent Strut Thickness 65 µm
Drug Sirolimus
Polymer Biodegradable + Biocompatible
Delivery system Rapid Exchange
Drug Dose 1.25μg/mm2

Size Chart

DIAMETER(MM)   LENGTH(MM)    
  30  40 50 60
2.75-2.25 mm BIM27522530 BIM27522540 BIM27522550 BIM27522560
3.00-2.50 mm BIM30025030 BIM30025040 BIM30025050 BIM30025060
3.50-2.75 mm BIM35027530 BIM35027540 BIM35027550 BIM35027560
3.50-3.00 mm BIM35030030 BIM35030040 BIM35030050 BIM35030060

 

Clinical Data

STUDY NAME TYPE OF STUDY TOTAL PATIENTS STATUS LINKS
SPONSOR INITIATED STUDIES
Morph India Study Prospective study 450 Ongoing Know more
Morpheus-Global Registry Prospective study 400 Ongoing Know more
Morph-BGM Study Prospective study 100 Ongoing Know more
INVESTIGATOR INITIATED STUDIES
BioMime Morph Multicenter study Observational study 362 Completed Know more
BioMime Morph study, Valencia, Spain Prospective clinical cohort study 50 Completed Know more
BioMime Morph study, Russia Prospective, Observational study 85 Completed Know more
BioMime Morph study, The Netherlands Observational study 49 Completed Know more
BioMime Morph study, Spain Observational study 628 Completed Know more

 

Product IFU

Note: IFU will be displayed after MDR Certification

Enquire
Now